News | Cardiac Diagnostics | February 15, 2019

IBM and Broad Institute Launch AI Initiative for Cardiovascular Disease Risk Prediction

New partnership will expand power of polygenic risk scores to help clinicians predict and prevent disease

IBM and Broad Institute Launch AI Initiative for Cardiovascular Disease Risk Prediction

February 15, 2019 — IBM Watson Health and the Broad Institute of MIT and Harvard are launching a research partnership aimed at developing powerful predictive models that will enable clinicians to identify patients at serious risk for cardiovascular disease. This three-year project will incorporate population- and hospital-based biobank data, genomic information, and electronic health records to build upon and expand the predictive power of polygenic scoring. The project will also plan to make insights and tools widely available to the research community, including methods to calculate an individual’s risk of developing common diseases based on millions of variants in the genome.

“I’m excited to build upon the advances we’ve made in polygenic risk scoring utilizing vast amount of genomic data,” said Sekar Kathiresan, director of the Center for Genomic Medicine at Massachusetts General Hospital (MGH) and institute member and director of the Cardiovascular Disease Initiative at the Broad Institute. “By coupling clinical data with genomic data, there is an exceptional opportunity to make polygenic risk scoring more robust and powerful, and ultimately transformative for patient care. Such transformation could never happen without these kinds of partnerships.”

Kathiresan will direct this new initiative along with Anthony Philippakis, chief data officer of the Broad Institute who trained as a cardiologist at Brigham and Women’s Hospital.

In recent years, scientists at the Broad Institute, MGH and Harvard Medical School have advanced a new kind of genome analysis called polygenic risk scores. The scores can identify subsets of the population who have a significantly higher risk of developing serious common diseases, including coronary artery disease, atrial fibrillation or breast cancer.

These tests, which use information from more than 6 million sites of variation in the human genome to ascertain risk for disease, can flag greater likelihood of developing serious conditions well before symptoms appear. Research suggests that up to 25 million people in the U.S. may be at more than triple the normal risk for coronary artery disease, and millions more may be at similar elevated risk for the other conditions, based on genetic variation alone. Such genomic information could allow physicians to find these individuals and intervene to prevent disease.

But more work needs to be done before this research is incorporated into clinical care, and that is the role of this new three-year partnership.

IBM and Broad Institute will expand the power of polygenic scoring by building artificial intelligence (AI)-based models for cardiac disease risk based on genomic information combined with patients' medical records and biomarkers. This project will also incorporate direct feedback from doctors and caregivers, all with the ultimate goal of assimilating such power into the medical system.

“With this new partnership, we have the opportunity to develop new approaches for the understanding and prediction of disease,” said Eric S. Lander, president and founding director of the Broad Institute. “I’m hopeful this will help advance precision medicine for patients.”

For more information:,

Related Content

New Consensus Document Explores Ethical Use of AI in Radiology
News | Artificial Intelligence | March 05, 2019 | Jeff Zagoudis, Associate Editor
The American College of Radiology (ACR) is one of seven professional societies behind a new consensus document on the...
RSNA Offers First U.S. Spotlight Course on Artificial Intelligence
News | Artificial Intelligence | March 05, 2019
The Radiological Society of North America (RSNA) announced an expansion of its artificial intelligence (AI) education...
ACC Future Hub

Presenter delivers pitch at last year’s ACC Future Hub. This year during ACC.19, entrepreneurs will pitch software and hardware specific to cardiology in two categories– artificial intelligence and digitally enabled medical devices. (Image courtesy of ACC)

Feature | Artificial Intelligence | March 01, 2019 | By Greg Freiherr
Entrepreneurs to pitch innovative ideas at ACC
Siemens Healthineers Demonstrates Artificial Intelligence, Healthcare Digitalization at HIMSS19
News | Artificial Intelligence | February 13, 2019
At the 2019 Healthcare Information and Management Systems Society (HIMSS) global conference and exhibition, Feb. 11-15...
Medical Imaging AI Fundings Tops $1.2 Billion Worldwide
News | Artificial Intelligence | February 04, 2019
In 2018, capital investment in companies developing artificial intelligence (AI)-enabled medical image analysis...
Siemens Healthineers Debuts AI-Rad Companion Chest CT
News | Artificial Intelligence | January 25, 2019
January 25, 2019 — Siemens Healthineers presented its first intelligent software assistant for radiology, the AI-Rad
Artificial Intelligence in medical imaging was the top trend and buzz at RSNA 2018.

Artificial intelligence in medical imaging was the major buzz at RSNA 2018. The expo floor had a dedicated area just to highlight artificial intelligence software for medical imaging. More than 150 vendors on the expo floor were showing software using some level of AI or deep learning. 

Feature | Artificial Intelligence | January 17, 2019 | Dave Fornell, Editor
Artificial intelligence (AI) was by far the hottest trend discussed in sessions and across the expo floor at the worl
Artificial Intelligence Advances Threaten Privacy of Health Data
News | Artificial Intelligence | January 04, 2019
Advances in artificial intelligence (AI) have created new threats to the privacy of people's health data, a new...
Videos | Artificial Intelligence | December 12, 2018
This is a quick video tour of the Machine Learning Showcase at the ...
Overlay Init